Adducin: A Potential Drug Target and Biomarker (P11979)

Target Name: Adducin

NCBI ID: P11979

Adducin

Other Name(s): None

Adducin: A Potential Drug Target and Biomarker

Adducin, a protein found in various tissues throughout the body, has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and various functions make it an attractive target for researchers to study and develop new treatments.

The protein adducin is a member of the superfamily of cytoplasmic proteins, which are involved in various cellular processes, including cytoskeletal organization, cytoplasmic transport, and signaling. Adducin is a 21-kDa protein that is expressed in various tissues, including muscle, heart, brain, and organs. Its function in these tissues is not well understood, but it is known to play a role in the regulation of cellular processes, such as cell adhesion, migration, and signaling.

One of the key features of adducin is its ability to interact with various signaling molecules, including TGF-灏?, a well-known cytokine that plays a role in cell growth, differentiation, and survival. TGF-灏? signaling is involved in many diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Therefore, the interaction between adducin and TGF-灏? makes it an attractive target for drug development.

In addition to its role in TGF-灏? signaling, adducin has also been shown to play a role in the regulation of actinin, a protein that is involved in cell-cell adhesion and is composed of multiple subunits. Actinin is a critical protein that helps maintain the integrity of tissues and has been implicated in many diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Therefore, the regulation of actinin by adducin may also be a potential drug target.

The structure of adducin has also been the subject of investigation, and it has been shown to have a unique folds that are involved in its function. Adducin has a single transmembrane domain and a cytoplasmic tail that is involved in its stability and interactions with other molecules. The cytoplasmic tail of adducin contains a region that is involved in its stability and has been shown to play a role in its regulation.

The potential drug targets for adducin are vast, and there is evidence to suggest that it may have a role in many diseases. For example, adducin has been shown to be involved in the regulation of TGF-灏? signaling in cancer cells, which may make it a potential target for anti-cancer drugs. Additionally, the regulation of actinin by adducin may also be a potential drug target for neurodegenerative diseases, as actinin is involved in the regulation of many neural functions.

In conclusion, adducin is a protein that has been identified as a potential drug target and biomarker for various diseases. Its unique structure and various functions make it an attractive target for researchers to study and develop new treatments. While more research is needed to fully understand its role in these diseases, the potential for adducin as a drug target and biomarker is an exciting area of study.

Protein Name: Adducin

The "Adducin Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Adducin comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets